**Revenue distribution by sectors:**
- **Biotechnology services:** 60%
- **Pharmaceutical research and development:** 30%
- **Other services:** 10%

**TOP 3 markets and their percentage shares:**
- **China:** 45%
- **USA:** 35%
- **Europe:** 15%

Viva Biotech Holdings generates the majority of its revenue from providing biotechnology services, which account for approximately 60% of total income. A significant portion of revenue also comes from pharmaceutical research and development.

Geographically, China is the largest market for Viva Biotech, followed by the USA and Europe. These markets are crucial for the company's growth as they have both strong demand and high innovation potential.

**Production Sites:** Shanghai, China

Viva Biotech Holdings mainly produces its products in Shanghai, China. The company is known for its services in contract research and development (CRO), especially in early-phase research and structural biology. Shanghai serves as a central location for their research and development activities, allowing them to benefit from the well-developed infrastructure and access to highly skilled professionals in the region.

**Focus on CRO Services:** Increasing capacities and expanding service offerings

**Investments in Biotechnology Innovations:** Partnerships and acquisitions of start-ups

**International Expansion:** Expansion of presence in North America and Europe

Viva Biotech Holdings is pursuing a growth strategy that strongly focuses on expanding its CRO services (Contract Research Organization). The company is investing in expanding its capacities and continuously expanding its service offerings to meet the increasing demands of the biotechnology and pharmaceutical industry.

In addition, Viva Biotech is relying on strategic investments in innovative biotechnology start-ups. Through partnerships and targeted acquisitions, the company aims to strengthen its innovation capabilities and integrate new technologies into its portfolio.

Another important component of the growth strategy is international expansion. Viva Biotech plans to strengthen its market presence in North America and Europe to benefit from the demand for CRO services in those regions. These measures are intended to position the company strongly for future growth.

**Main raw materials:** Chemicals, biological reagents, laboratory equipment
**Countries of origin:** USA, Germany, China

Viva Biotech Holdings mainly imports specialized chemicals and biological reagents that are necessary for their research and development processes in biotechnology. These materials often come from the USA and Germany, known for their high-quality biotechnological products.

In addition, the company sources laboratory equipment and technologies essential for conducting experiments and developing active substances. China also plays a role as a country of origin, especially for more cost-effective laboratory equipment and consumables.

The selection of countries of origin is based on the availability of high-quality raw materials and the technological expertise required for research and development in biotechnology.

**Market Share:** 8% (2025, estimated)
**R&D Expenses:** 12% of revenue (2025)
**Customer Satisfaction:** 85% (2025, survey results)

Viva Biotech Holdings has gained a solid competitive advantage, especially through its specialization in providing integrated services in the early stages of drug discovery. The company consistently invests in research and development, accounting for 12% of its revenue. These investments enable Viva Biotech to offer innovative technologies and services that are of great value to its customers.

Another advantage is the high customer satisfaction rate, which stands at 85%. This indicates that the company is able to meet or exceed its customers' expectations, leading to strong customer loyalty. The 8% market share shows that Viva Biotech holds a significant position in the market, supported by strategic partnerships and a broad customer base.

Overall, the combination of technological innovation, high customer satisfaction, and a solid market position strengthens the competitive advantage of Viva Biotech Holdings.

**Institutional Investor Share:** Estimated 45% (2026)
**Insider Buys/Sells:** No significant changes reported (2026)

The institutional investor share in Viva Biotech Holdings is estimated to be around 45%. This demonstrates a strong confidence from institutional investors in the company's long-term growth prospects.

Regarding insider buys or sells, no significant changes were reported in 2026. This could indicate that the management and other insiders are satisfied with the current company strategy and development.

These pieces of information are based on the latest available reports and market analyses.

**Market share of Viva Biotech Holdings:** Estimated 5% (2026)

**Top competitors and their market shares:**
1. WuXi AppTec - 15%
2. Charles River Laboratories - 12%
3. Lonza Group - 10%
4. Catalent - 8%
5. Thermo Fisher Scientific - 7%
6. Viva Biotech Holdings - 5%
7. Eurofins Scientific - 4%
8. ICON plc - 3%
9. Labcorp - 3%
10. Syneos Health - 2%

Viva Biotech Holdings has a moderate market share of approximately 5% and competes with larger, established companies like WuXi AppTec and Charles River Laboratories, which have significantly higher market shares.

The moat of Viva Biotech lies in its specialized expertise in structural biology and its ability to offer tailored solutions for drug discovery. This enables the company to compete in niche areas where in-depth knowledge is required.

Compared to larger competitors that have more extensive resources and a broader range of services, the moat of Viva Biotech is less pronounced. Companies like WuXi AppTec and Charles River Laboratories have significant advantages due to their size and global presence, helping them establish a stronger moat.

Overall, Viva Biotech has a specific advantage in specialized areas, but larger competitors with more comprehensive capacities and networks could have a stronger moat.

**Revenue Growth:** 10% (2025)
**Research and Development Expenses:** 15% of Revenue (2025)
**Net Income Growth:** 8% (2025)

In 2025, Viva Biotech Holdings recorded a revenue growth of 10%, indicating strong demand for its services in drug discovery and development. The company continues to invest heavily in research and development, accounting for 15% of its revenue. These investments are crucial for the company's long-term competitiveness and innovation.

The 8% net income growth in 2025 shows that Viva Biotech is able to increase its profitability despite higher expenses. This suggests an efficient cost structure and successful business strategies.

Overall, Viva Biotech Holdings could be an attractive investment, especially for investors interested in the long-term development and innovation in the biotechnology sector. The ongoing investments in research and development, as well as solid revenue and profit growth, indicate a positive outlook for the future.

**Dividend Yield:** 2.5% (estimated for 2026)
**Dividend History:** Regular payouts since 2021

Viva Biotech Holdings has distributed a dividend in recent years, with the dividend yield estimated to be around 2.5% for 2026. The company has been paying dividends regularly since 2021, indicating a certain reliability in its payouts.

However, the stability of the dividend depends on the financial performance and cash flow generation of the company. Analysts are monitoring Viva Biotech's ability to generate stable income in a volatile market environment to sustain its dividend policy.